Rat Models of Endotoxin-Induced Uveitis in the MICRON Literature
About the MICRON Research Literature
These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.
All publication counts and figures reflect the complete indexed research collection.
Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.
Understanding Endotoxin-Induced Uveitis
EIU is provoked by bacterial lipopolysaccharide, producing acute, predominantly anterior inflammation that develops within hours, peaks around a day and typically resolves spontaneously over the next several days.
Endotoxin-Induced Uveitis in Experimental Research
EIU is an innate rather than adaptive response, which makes it fast, reproducible and well suited to testing anti-inflammatory intervention.
Its resolution is also its bound: a self-limiting acute episode does not model chronic or recurrent uveitis.
Rat Models of Endotoxin-Induced Uveitis
For autoimmune uveitis the Lewis rat is a classical host: it is highly susceptible to immunization with retinal antigens and develops an acute, severe EAU that can be graded reproducibly.
Strain also matters in endotoxin-induced uveitis, where Lewis rats are highly susceptible but Wistar, Sprague-Dawley and other strains are also used.
Across these induced models, immunologic susceptibility is a major determinant of strain choice.
Published MICRON Research: Endotoxin-Induced Uveitis in Rats
This page lists 4 papers from the MICRON literature, published 2016 to 2024, that study endotoxin-induced uveitis in rats.
Of these publications:
- 4 studies used rats as the primary endotoxin-induced uveitis disease model.
Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published endotoxin-induced uveitis research.
Which imaging and experimental techniques are used in these studies?
| Technique | Papers |
|---|---|
| Intravitreal Injection / Delivery | 4 |
| Optical Coherence Tomography | 3 |
| Topical Ophthalmic Drug Delivery | 3 |
| Fundus Fluorescein Angiography | 2 |
| Electroretinography | 1 |
| Laser Photocoagulation Models | 1 |
| Ocular Implant (Unresolved Sense) | 1 |
| Ocular Implants / Sustained Release | 1 |
Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.
Capabilities and Limitations of Imaging Techniques
A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications. The others appear in the table and not here: Ocular Implant (Unresolved Sense).
Intravitreal Injection / Delivery
Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.
Optical Coherence Tomography
Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.
As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).
Topical Ophthalmic Drug Delivery
A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.
Fundus Fluorescein Angiography
Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.
This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.
Electroretinography
Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.
Laser Photocoagulation Models
A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.
Ocular Implants / Sustained Release
A sustained-release system holds a compound in or on the eye and lets it out gradually, so exposure is maintained from one placement rather than from a series of doses. The class spans polymer and non-polymer solid depots, injectable and particulate carriers, and reservoir devices; the release period belongs to the platform and not to the route, and runs from days to years. What the approach is for is to separate the dosing interval from the procedure interval, holding exposure at the target for as long as the question runs, whether that is the few weeks of a short-lived model or the span of a lifelong disease, without an intervention for each dose. What it gives up is control after placement. The release profile has to be measured rather than assumed, altering or ending delivery may require a further procedure, biodegradable systems behave differently from removable ones, and the carrier sits in contact with ocular tissue, so how the eye tolerates it is part of the result and not a precondition of it.
Which MICRON systems and add-ons appear?
| Instrument | Papers |
|---|---|
| Anterior Segment Imaging System | 2 |
| Image-Guided OCT | 2 |
| MICRON III | 2 |
| MICRON IV | 2 |
| Image-Guided Laser | 1 |
Which strains and genetic lines are used?
| Strain | Papers | Reported as |
|---|---|---|
| Wistar | 2 | |
| Brown Norway | 1 | |
| Sprague-Dawley | 1 |
Which other species appear alongside?
| Species | Papers |
|---|---|
| Rabbit | 2 |
| Mouse | 1 |
What other conditions are recorded on the same papers?
| Disease | Papers |
|---|---|
| Uveitis (General) | 3 |
| Choroidal Neovascularization | 1 |
| Diabetes Mellitus, Type 1 | 1 |
| Diabetic Retinopathy | 1 |
| Neuromyelitis Optica Spectrum Disorder | 1 |
| Retinal Ganglion Cell Degeneration | 1 |
Which MICRON configurations appear in this work?
Configurations recorded in these papers, and the techniques recorded alongside them.
| MICRON configuration | Papers | Most frequent techniques recorded alongside |
|---|---|---|
| Anterior Segment Imaging System | 2 | Intravitreal Injection / Delivery (2), Topical Ophthalmic Drug Delivery (2), Fundus Fluorescein Angiography (1) |
| Image-Guided OCT | 2 | Intravitreal Injection / Delivery (2), Optical Coherence Tomography (2), Fundus Fluorescein Angiography (1) |
| MICRON III | 2 | Intravitreal Injection / Delivery (2), Electroretinography (1), Optical Coherence Tomography (1) |
| MICRON IV | 2 | Fundus Fluorescein Angiography (2), Intravitreal Injection / Delivery (2), Optical Coherence Tomography (2) |
| Image-Guided Laser | 1 | Fundus Fluorescein Angiography (1), Intravitreal Injection / Delivery (1), Laser Photocoagulation Models (1) |
The papers
| Year | Title | Journal | Role of focal species | MICRON products | Links |
|---|---|---|---|---|---|
| 2024 | RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models. | Frontiers in Pharmacology | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2023 | Cationic Nano-Lipidic Carrier Mediated Ocular Delivery of Triamcinolone Acetonide: A Preclinical Investigation in the Management of Uveitis. | Life | Disease model | Anterior Segment Imaging System, MICRON III | DOI · reSEARCH |
| 2021 | Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery. | Nature Communications | Disease model | Anterior Segment Imaging System, Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2016 | Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G. | Journal of Neuroinflammation | Disease model | Image-Guided OCT, MICRON III | DOI · reSEARCH |
Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.